Indaptus Therapeutics (INDP) Retained Earnings (2020 - 2026)
Indaptus Therapeutics (INDP) posted quarterly Retained Earnings of $83.9 million for Q1 2026, up 24.16% year-over-year from $67.6 million in Q1 2025, and down 0.55% quarter-over-quarter from $84.4 million in Q4 2025.
Indaptus Therapeutics (INDP) Retained Earnings (2020 - 2026) Analysis & Trends
Indaptus Therapeutics' Retained Earnings history runs 7 years deep, the most recent figure standing at $83.9 million for Q1 2026.
- In Q1 2026, Retained Earnings rose 24.16% year-over-year to $83.9 million; the TTM figure through Mar 2026 stood at $83.9 million (up 24.16% YoY), while the FY2025 annual figure was $84.4 million, up 239.66% from the prior year.
- Retained Earnings for Q1 2026 stood at $83.9 million, down from $84.4 million in the prior quarter.
- The five-year high for Retained Earnings was $84.4 million in Q4 2025, with the low at -$60.4 million in Q4 2024.
- The 5-year median for Retained Earnings is $96434.0 (2022), against an average of $16.4 million.
- Peak annual rise in Retained Earnings reached 59432.57% in 2023, while the deepest fall reached 370792.53% in 2023.
- Indaptus Therapeutics' Retained Earnings stood at $96434.0 in 2022, then jumped by 59432.57% to $57.4 million in 2023, then sank by 205.28% to -$60.4 million in 2024, then soared by 239.66% to $84.4 million in 2025, then fell by 0.55% to $83.9 million in 2026.
- Business Quant data shows INDP's Retained Earnings at $83.9 million in Q1 2026, $84.4 million in Q4 2025, and $77.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 4.38 Bn |
| 10 | Indaptus Therapeutics | 146.91 Mn | 135.35 Mn | - | 95.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 95.66 Mn |
| Mar 31, 2026 | 83.94 Mn |
| Dec 31, 2025 | 84.41 Mn |
| Sep 30, 2025 | 77.76 Mn |
| Jun 30, 2025 | 68.52 Mn |
| Mar 31, 2025 | 67.61 Mn |
| Dec 31, 2024 | -60.44 Mn |
| Sep 30, 2024 | -56.31 Mn |
| Jun 30, 2024 | 59.32 Mn |
| Mar 31, 2024 | 58.50 Mn |
| Dec 31, 2023 | 57.41 Mn |
| Sep 30, 2023 | -41.40 Mn |
| Jun 30, 2023 | -37.50 Mn |
| Mar 31, 2023 | -34.20 Mn |
| Dec 31, 2022 | 96,434.00 |
| Sep 30, 2022 | -26.34 Mn |
| Jun 30, 2022 | -22.90 Mn |
| Mar 31, 2022 | -9,221.00 |
| Dec 31, 2021 | 51.49 Mn |
| Sep 30, 2021 | -12.45 Mn |